Key result
Active atrioventricular synchronous pacing induced significant quality of life improvements of 9-44% in patients with drug-refractory hypertrophic obstructive cardiomyopathy.
Why the study?
Does atrioventricular synchronous pacing improve quality of life in drug-refractory patients with hypertrophic obstructive cardiomyopathy?
RCT (n=80)
Double-blind
crossover
Does atrioventricular synchronous pacing improve quality of life in drug-refractory patients with hypertrophic obstructive cardiomyopathy?
Atrioventricular synchronous pacing significantly improves quality of life in patients with drug-refractory hypertrophic obstructive cardiomyopathy.
Answers are grounded in this paper and cite their sources.
AV synchronous pacing improves QoL in HOCM; supports its use for symptom relief and confirms benefit in placebo-controlled crossover design.
AIMS: Atrioventricular synchronous pacing exerts beneficial effects, including reduction of left ventricular outflow tract gradients, in patients with hypertrophic obstructive cardiomyopathy. The Pacing in Cardiomyopathy study was initiated to explore the effects of pacing in a double-blind randomized crossover fashion. The aims were to ascertain the beneficial effects of pacing in a controlled study and to rule out a placebo effect by pacing. This paper deals with the outcome of pacing on quality of life during 1 year of follow-up. METHODS: Quality of life was evaluated with the Karolinska questionnaire, validated for patients paced for bradyarrhythmias and ischaemic heart disease. Drug-refractory patients with hypertrophic obstructive cardiomyopathy were recruited for the study and after a temporary pacing procedure implanted with permanent pacemakers. Patients were randomized to two study arms defining the sequence of pacemaker programming. In one arm the pacemaker was inactive, in the other active. After 3 months the pacemaker was reprogrammed to the alternate mode and a further 3 months followed. After this period subsequent pacemaker programming corresponded to the mode preferred by the patient. A last assessment was made 1 year after baseline examinations. RESULTS: Eighty patients completed the first crossover period and 75 completed the full 1 year of follow-up. Active pacing induced significant quality of life improvements, in the order of 9-44%, regardless of programming sequence. Discontinuation of pacing after a first active period resulted in the return of symptoms. Fourteen patients requested early reprogramming after having been programmed to inactive pacing after a first period of active pacing. Seventy-six patients preferred active pacing after the crossover period. A further 6 months of pacing induced progressive improvement in symptoms already favourably influenced. CONCLUSION: Atrioventricular synchronous pacing has a profound beneficial effect on most domains of quality of life in patients with hypertrophic obstructive cardiomyopathy refractory to drug treatment.
No takes yet. Share an insight, caveat, or question.
Fredrik Gadler (1999) conducted an RCT in hypertrophic obstructive cardiomyopathy (n=80). Atrioventricular synchronous pacing vs. Inactive pacing was evaluated on Quality of life (Karolinska questionnaire). Active atrioventricular synchronous pacing induced significant quality of life improvements of 9-44% in patients with drug-refractory hypertrophic obstructive cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: